Since the first public demonstration of ether anaesthesia in 1846, there has been concern about anaesthetic-induced neurotoxicity. Shortly after observing this demonstration, Henry Jacob Bigelow, 1 a Professor of Surgery at Massachusetts General Hospital, began characterising the postetherized state of these particular patients. ' The character of the lethargic state, which follows this inhalation, is peculiar', he initially remarked. 1 He later provided the following vivid description of a patient: '[the] narcotism was complete during more than twenty minutes, the insensibility approached to coma'. More than a century later, Bedford 2 suggested in 1955 that minor dementias and even catastrophic mental impairment sometimes occur in the aftermath of general anaesthesia. He went on to recommend, 'operations on elderly people should be confined to unequivocally necessary cases'. 2 In 1961, Eckenhoff and colleagues 3 characterized the phenomenon of 'post-anaesthetic excitement', which occurred with disproportionate frequency in paediatric patients. Today, the question of whether anaesthetic agents at clinically relevant concentrations are neurotoxic represents a major clinical and scientific controversy in the field.
Laboratory studies suggest that commonly used anaesthetics may induce neurotoxicity through a variety of mechanisms, although the following have been particularly implicated: cellular and metabolic stress (leading to neuroapoptosis), promulgation of Alzheimer's disease neuropathology, and toxic overdose.
4e8 Post-anaesthetic cognitive deficits have also been identified in animal models. 9, 10 However, clinical evidence in humans is inconclusive, with the current body of data not demonstrating a compelling link between anaesthetic exposure and persistent cognitive decline. 11, 12 Explanatory studies investigating specific neurological end points amongst different general anaesthetics remain at a nascent stage and demonstrate inconsistent results. 13, 14 Unfortunately, finding an ideal model for studying the purported neurotoxicity of anaesthetic drugs has proved challenging. It is possible that the neurotoxic effects observed in cell cultures and short-term in vivo laboratory models do not translate to clinically meaningful pathology. In the perioperative setting, anaesthetic administration occurs concomitantly with relevant confounders, such as surgical stress, inflammation, pain, polypharmacy, pre-existing comorbidities, and sleep disturbances. Thus, studying anaestheticspecific neurotoxicity with appropriate controls in the real world is challenging.
New scientific model for anaesthetic neurotoxicity?
In recent years, endovascular stroke therapy has received considerable attention after multiple trials demonstrating positive outcomes. 15, 16 The pathological target of this intervention involves large-vessel occlusion with a severely ischaemic core and susceptible penumbra region, which includes brain cells with tenuous viability. Cells in this penumbra region receive some collateral perfusion, but signs of cellular and metabolic stress are present, and infarction ensues without timely restoration of blood flow. Furthermore, the extent of the stroke and long-term neurological outcomes might be related to the anaesthetic technique. Retrospective data from multiple studies show worse stroke outcomes in patients who received general anaesthesia compared with conscious sedation. 17, 18 These results could certainly have been interpreted to suggest that the practice of administering general anaesthesia for stroke interventions was clinically inappropriate. Before a change in practice, however, important potential confounders (e.g. baseline stroke severity, blood pressure) in these retrospective studies needed to be addressed. 17, 18 The Sedation vs Intubation for Endovascular Stroke Treatment (SIESTA) trial prospectively tested conscious sedation vs general anaesthesia in the setting of acute ischaemic stroke in the anterior circulation. 19 The 150-patient trial had a singlecentre design with a dedicated stroke-intervention team that helped minimize institutional and provider variability. The baseline patient and stroke characteristics were similar, and there was no clinically or statistically significant difference in the primary outcome, the National Institutes of Health Stroke Scale (NIHSS) at 24 h, between the two groups {mean difference e0. Months after the SIESTA trial results were reported, the Anesthesia During Stroke (AnStroke) trial was published, and these concerns were partially addressed. 20 This was another single-centre trial, in which 90 anterior circulation stroke patients were randomized to conscious sedation or general anaesthesia. General anaesthesia was induced with propofol and remifentanil, and anaesthesia was maintained with sevoflurane and remifentanil. The conscious-sedation group received remifentanil. Unlike the SIESTA trial, intraoperative blood pressure, glucose, and PaCO 2 were measured in each group. No clinically or statistically significant differences were found between groups for any of these variables. The primary outcome was achieving a mRS score 2 at 3 months, which occurred in 42.2% of patients in the general-anaesthesia group and in 40.0% of patients in the conscious-sedation group (P¼1.00). There were also no consequential differences between groups in any of the secondary outcomes examined, including successful recanalization rates, 91.1% vs 88.9% (P¼1.00); infarction volume, 20 ml (10e100) vs 20 ml (10e54) (P¼0.53); recurrent stroke incidence, 6.7% vs 11% (P¼0.71); mortality (13.3% in both groups; P¼1.00); or NIHSS scores at 24 h, 8 (3e5) vs 9 (2e15; P¼0.60). Of note, the mean (SD) age of general-anaesthesia patients in the SIESTA trial was 71.8 (12.9), and the median (inter-quartile range) age of generalanaesthesia patients in the AnStroke trial was 73 (65e80). This is relevant because anaesthetics have been proposed to be particularly injurious to the brains of older people, 21 and older surgical patients are prone to adverse neurological outcomes, such as delirium 22 and stroke. 23 Finally, preliminary results from the 128-patient General or Local Anesthesia in Intra Arterial Therapy (GOLIATH) trial were reported recently at the European Stroke Organisation Conference. 24 There was no significant difference (P¼0. The results from these three recent trials are consistent with findings from the General Anaesthesia versus Local Anaesthesia for Carotid Surgery Trial. 25 In this study, patients with carotid-artery stenosis were randomized to carotid endarterectomy under general anaesthesia or local anaesthesia, and neurological outcomesdincluding strokedwere measured. This carotid-surgery model parallels that of strokeintervention therapy, as cerebral blood flow can be significantly limited in the setting of carotid-artery clamping, and ischaemia can ensue without restoration of blood flow (e.g. shunting). Vulnerable neurones in this setting may also be predisposed to neurotoxic injury; however, no difference in the composite outcome of strokedincluding retinal infarctiondor mortality at 30 days was identified between the two groups [4.6% vs 4.2%; difference ¼0.44% (95% CI 0.96e1.86%); P¼0.5].
With any proposed anaesthetic neurotoxicity study model, dosing information is an important element to consider. Indeed, neurotoxicity risk may follow a dose-dependent pattern, whereby increased exposure portends higher risk. 8 However, a post hoc analysis from the Intraoperative Hypothermia for Aneurysm Surgery Trial suggests that additional anaesthetic delivery, implemented for achieving burst suppression during cerebral-aneurysm surgery in patients with subarachnoid haemorrhage, had no clinically detectable effect on neurological outcome. 26 This is significant because tem- 27 and intraoperative burst suppression might be an independent risk factor for postoperative delirium. 28 Final results from the GOLIATH trial may allow for additional evaluation of neurological injury and outcomes in relation to anaesthetic dosing. 29 These studies were conducted in order to answer a clinical question: is general anaesthesiadand its attendant consequencesdsafe for patients undergoing procedures related to the cerebrovascular system (e.g. endovascular intervention, carotid endarterectomy)? However, we would argue that these clinical studies focused on stroke actually have broader implications related to the question of anaesthetic neurotoxicity for non-cerebrovascular interventions, especially in older surgical patients. Findings from trials studying the effects of general anaesthesia on stroke pathophysiology can serve as a novel scientific model for studying anaesthetic neurotoxicity in humans. Stroke represents a known situation in which the brain is especially vulnerable to injury. We suggest that the recent randomized controlled data gathered for the primary purpose of understanding the best clinical care for stroke patients can be reinterpreted to assess whether general anaesthesia is injurious to vulnerable neurons in humans.
This strategy is motivated by two primary observations: first, there is a known neurological insult with a neuronal population (i.e. the penumbra) that is susceptible to injury, and secondly, there is equipoise about general anaesthesia and conscious sedation. Neurological effects specific to anaesthetics can be studied in a relatively isolated manner, as there is no major surgical intervention or surgery-associated stress response in stroke-intervention patients, and baseline patient characteristics, comorbidities, and stroke characteristics are well balanced. Ultimately, by leveraging this strokeresearch framework as a scientific model, the field can advance the understanding of clinically relevant anaesthetic neurotoxicity in the older brain. As recently described during the British Journal of Anaesthesia seminar on anaesthetic neurotoxicity and neuroplasticity, 30 the clinical trial design for addressing neurotoxicity depends on the specific questions to be answered, and results from these stroke trials could address purported toxicity in the older, vulnerable brain. 21 Targeted neurological outcomes that reflect proposed models of neurotoxicity could be investigated accordingly. First, measuring the final stroke characteristics in both groups (e.g. final infarct volume, stroke recurrence) could address the question of anaesthetic-induced neuroapoptosis and cellular metabolic stress. If general anaesthetics indeed initiate a cellular cascade of events that leads to neural cell damage and death, 7 then patients undergoing stroke rescue in the setting of general-anaesthetic administration could accordingly have a larger infarct volume and a possibly higher risk of short-term stroke recurrence than patients undergoing conscious sedation. Vulnerable penumbral neurones in these patients may be particularly prone to such cellular events. None of the trials discussed earlierdSIESTA, AnStroke, or GOLIATHddemonstrated larger infarct volumes in stroke patients receiving general anaesthesia. 19 20 24 In fact, the final infarct volume was significantly larger in the conscioussedation group in the GOLIATH trial. 24 Furthermore, patients randomized to general anaesthesia in the AnStroke trial had similar stroke recurrence rates compared with those who underwent sedation. 20 Thus, these trials do not present evidence of larger stroke volume or increased recurrence risk in stroke patients undergoing general anaesthesia. Secondly, assessing for precipitation of dementia and performing longitudinal, post-stroke cognitive-function testing could address related models of neurotoxicity. For example, general anaesthetics have been shown to propagate amyloid-b and tauprotein pathophysiology in laboratory studies, 4e6 which are the pathophysiological hallmarks of Alzheimer's disease. 31, 32 Measuring cognitive trajectory and new-onset dementia in groups receiving general anaesthesia compared with conscious sedation could indicate whether such a pathophysiological burden exists. Additionally, covert stroke drives cognitive decline in the non-surgical setting, 33, 34 and comparing cognitive function between groups may also be indicative of new silent infarction not initially detected. Lastly, toxic overdose is an additional mechanism by which neural injury is proposed to occur. 8 By correlating anaesthetic exposure (e.g. cumulative dose, duration) with targeted measures, such as infarct volume, deficit scales, and disability burden, we could begin to evaluate the question of anaesthetic exposure and post-exposure neurological function. Although such efforts will not unambiguously settle whether these doses and studies are too small to detect signs of clinical neurotoxicity, they serve as a foundation for better addressing the issue in the older brain, and could reveal whether large, clinically significant effects become readily apparent during a period of known neural vulnerability. Additional prospective efforts are ongoing, 35 and multidisciplinary collaboration may be key to answering these questions. Finally, neuroprotective properties could be studied as well. As noted, the SIESTA trial and the GOLIATH trial showed improved mRS scores and reduced final infarct volume, respectively, in patients receiving general anaesthesia. This aligns with laboratory-model findings, in which isoflurane administration after stroke has been associated with reduced infarct size and improved neurological scores after 8 weeks. 36 These proposed benefits may be as a result of optimized cerebral metabolism and blood flow during ischaemic injury, although the clinical efficacy of this protective mechanism remains in question. 37 Nonetheless, volatile anaesthetics reduce cerebral metabolism whilst increasing cerebral blood flow, 38 and volatile agents have been associated with favourable outcomes after endovascular stroke rescue. 27 Certain volatile agents (e.g. sevoflurane) have also been associated with mild cognitive-impairment progression. 39 Thus, specific anaesthetic agents used in these trials should be included for analysis as well as for establishing associations with neurotoxicity or neuroprotection.
Limitations
There are notable limitations to the proposed model. Acute ischaemic stroke is distinct from the state of the brain in the routine perioperative setting. The neurobiological effects of anaesthetics, including those that could be neurotoxic, might vary depending on the presence or absence of ischaemia. Anaesthetics could conceivably exert neurotoxic effects in the absence of ischaemia (i.e. routine non-cerebrovascular surgery), but remain innocuous or confer neuroprotection during ischaemia. In fact, neuroprotection could mitigate any clinically significant neurotoxic effects that would otherwise be present. However, the proposed neurotoxic mechanisms of anaesthetics (i.e. cellular and metabolic stress) overlap considerably with the cellular and molecular foundations of ischaemic-penumbra pathophysiology. For example, volatile agents are posited to mediate the generation of reactive oxygen species, mitochondrial transition pore formation, massive calcium influx, pro-inflammatory cytokine release, and neuroapoptosis in the older brain. 21 These same mechanisms are also central components of ischaemic-penumbra pathophysiology (Fig. 1) . 40 Thus, we believe that endovascular-stroketherapy research may still serve as a valuable model for the targeted study of anaesthetic neurotoxicity in the older, vulnerable brain. Nonetheless, we acknowledge that acute stroke presents a distinct neurobiological milieu compared with the non-cerebrovascular surgical setting.
Conclusion
Recent randomized controlled trials trying to answer specific questions about safe clinical care for stroke patients undergoing general anaesthesia can be reinterpreted as a scientific model for anaesthetic neurotoxicity in humans that has implications well beyond the clinical condition of stroke or related interventions. Indeed, the findings from recent randomized clinical trials do not support the results from lowerquality observational studies of anaesthetic neurotoxicity, but they are consistent with randomized studies showing similar cognitive outcomes after cardiac surgery under general anaesthesia vs percutaneous coronary intervention with conscious sedation. 41e43 This highlights the potential danger of relying on low-quality evidence to inform scientific and public opinion. Low-quality evidence, including the seminal study by Bedford, 2 has formed the basis of the now entrenched hypothesis that surgery and general anaesthesia carry a longterm cognitive cost. 44 Importantly, available data from randomized endovascular stroke trials do not present evidence of neurological injury in older patients receiving general anaesthesia with either propofol or sevoflurane. This is compelling, given the vulnerability of penumbral neurones to pathophysiological insults. By investigating the final stroke characteristics, cognitive trajectory, and neurological outcomes related to cumulative anaesthetic exposure, we could gain important information as to whether general-anaesthetic agents are neurotoxic, neuroprotective, or innocuous in a specific and real-world brain vulnerability model that has scientific implications well beyond patients with cerebrovascular disease.
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In an effort to reduce the burden of under assessment and inadequate treatment of pain, the American Pain Society (APS) in 1996 instituted the "pain as the 5 th vital sign" campaign based on quality improvement guidelines published the previous year. 1 The aim of the campaign was to make pain assessment and measurement as important a measure of patient wellbeing as the existing four vital signs. The campaign was initially widely supported by many medical societies, regulatory organisations and pharmaceutical companies, 2e4 and was later adopted in the UK. 5 The APS guidelines suggested that pain should be recorded in a way that makes it highly visible and facilitates regular review by members of the health care team, and recommended use of unidimensional pain scales to record and chart pain intensity. In addition, it was suggested that elevated pain scores should act as a "red flag" to promote action. 1 Examples of recommended scales included the numeric rating scale (NRS), which is also known as the numerical pain scale (NPS); the visual analogue scale (VAS); and the categorical 4 point verbal rating scale (VRS). The NRS is the most commonly used pain scale, and patients are asked to rate their pain on a 0e10 scale. The VAS utilises a similar concept with patients marking a point on a 10 cm line. The categorical 4 point VRS involves asking the patient to state the severity of pain as none; mild; moderate, or severe. 6, 7 Over the past 20 years many US healthcare institutions adopted pain as the 5 th vital sign, and assessed pain using the self-reported unidimensional NPS. The United States Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey, used by the Centers for Medicare and Medicaid Services (CMS), is a patient satisfaction survey that facilitates reimbursement for US healthcare providers. The survey includes the question "How often did the hospital or provider do everything in their power to control your pain?" It has been suggested that this question embedded pain as the 5 th vital sign in US healthcare, but also had the unintended consequence of encouraging opioid administration in response to patients' self-reported numerical pain scores. 8 As a result, it has been suggested that the "pain as the 5 th vital sign" campaign with its reliance on the NPS directly contributed to the prescribed opioid epidemic that America is now experiencing. 
Prescribed opioid addiction in the US
Opioid misuse is now seen as a major health epidemic in the US, with social, medical and financial consequences. 9, 10 In 2016, it was estimated that the combined economic effect of the opioid epidemic (health care, labour, and criminal justice costs) was $92 billion. 9 Not surprisingly, there is now a presidential commission to combat the opioid drug addiction crisis. For many years it was believed that the risk of addiction to opioids prescribed for pain was rare. 2, 11 There are currently an estimated 2 million US residents aged 12 and older who are addicted to prescription opioids. 9 That the risk of developing addiction to opioids prescribed for acute pain management was rare was not only erroneous but in part propagated by pharmaceutical companies. 2, 12 In 2007, three drug company executives pleaded guilty to federal criminal charges that they misled regulators, doctors, and patients about the risk of addiction associated with prescribed opioids. 12 There have been at least 600,000 deaths in the US from prescribed opioids, and another 180,000 more are predicted by 2020.
9,10
Numerical pain scale used alone is misleading
Unidimensional self-reported pain scores have been implicated in contributing to the prescribed opioid epidemic and is associated with over-sedation. One US hospital reported that following introduction of treating pain according to a
